Abstract
The voltage-gated potassium channel Kv1.3 is an important target for the treatment of autoimmune diseases and asthma. Blockade of Kv1.3 by the sea anemone peptide K⁺-channel toxin from Stichodactyla helianthus (ShK) inhibits the proliferation of effector memory T lymphocytes and ameliorates autoimmune diseases in animal models. However, the lack of selectivity of ShK for Kv1.3 over the Kv1.1 subtype has driven a search for Kv1.3-selective analogues. In the present study, we describe N-terminally extended analogues of ShK that contain a negatively-charged Glu, designed to mimic the phosphonate adduct in earlier Kv1.3-selective analogues, and consist entirely of common protein amino acids. Molecular dynamics simulations indicated that a Trp residue at position [-3] of the tetrapeptide extension could form stable interactions with Pro377 of Kv1.3 and best discriminates between Kv1.3 and Kv1.1. This led to the development of ShK with an N-terminal Glu-Trp-Ser-Ser extension ([EWSS]ShK), which inhibits Kv1.3 with an IC₅₀ of 34 pm and is 158-fold selective for Kv1.3 over Kv1.1. In addition, [EWSS]ShK is more than 2900-fold more selective for Kv1.3 over Kv1.2 and KCa3.1 channels. As a highly Kv1.3-selective analogue of ShK based entirely on protein amino acids, which can be produced by recombinant expression, this peptide is a valuable addition to the complement of therapeutic candidates for the treatment of autoimmune diseases.
Keywords:
N-terminal extension; ShK; electrophysiology; molecular dynamics; potassium channels.
© 2015 FEBS.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Anti-Inflammatory Agents, Non-Steroidal / chemistry
-
Anti-Inflammatory Agents, Non-Steroidal / metabolism
-
Anti-Inflammatory Agents, Non-Steroidal / pharmacology*
-
Binding Sites
-
Cell Line
-
Cnidarian Venoms*
-
Drug Design*
-
Isoenzymes / antagonists & inhibitors
-
Isoenzymes / chemistry
-
Isoenzymes / metabolism
-
Kinetics
-
Kv1.3 Potassium Channel / antagonists & inhibitors*
-
Kv1.3 Potassium Channel / chemistry
-
Kv1.3 Potassium Channel / genetics
-
Kv1.3 Potassium Channel / metabolism
-
Mice
-
Models, Molecular*
-
Molecular Dynamics Simulation
-
Mutant Proteins / chemistry
-
Mutant Proteins / metabolism
-
Mutant Proteins / pharmacology*
-
Neurotoxins / chemistry
-
Neurotoxins / genetics
-
Neurotoxins / metabolism
-
Neurotoxins / pharmacology
-
Oligopeptides / chemistry
-
Oligopeptides / genetics
-
Oligopeptides / metabolism
-
Oligopeptides / pharmacology
-
Patch-Clamp Techniques
-
Potassium Channel Blockers / chemistry
-
Potassium Channel Blockers / metabolism
-
Potassium Channel Blockers / pharmacology*
-
Protein Conformation
-
Recombinant Fusion Proteins / chemistry
-
Recombinant Fusion Proteins / metabolism
-
Recombinant Fusion Proteins / pharmacology
-
Recombinant Proteins / chemistry
-
Recombinant Proteins / genetics
-
Recombinant Proteins / metabolism
-
Sea Anemones
-
Structure-Activity Relationship
Substances
-
Anti-Inflammatory Agents, Non-Steroidal
-
Cnidarian Venoms
-
Isoenzymes
-
Kcna3 protein, mouse
-
Kv1.3 Potassium Channel
-
Mutant Proteins
-
Neurotoxins
-
Oligopeptides
-
Potassium Channel Blockers
-
Recombinant Fusion Proteins
-
Recombinant Proteins